Thomas Fletcher Tedder, Ph.D., (born May 14, 1956) is an American immunologist. He is best known for his work in the fields of

B lymphocyte B cells, also known as B lymphocytes, are a type of white blood cell of the lymphocyte subtype. They function in the humoral immunity component of the adaptive immune system. B cells produce antibody molecules which may be either secreted ...

biology and regulation. He is currently the Alter E. Geller Professor for Research in Immunology at Duke University.

Career

Tedder received his Ph.D. in molecular cell biology from the

University of Alabama The University of Alabama (informally known as Alabama, UA, or Bama) is a public research university in Tuscaloosa, Alabama. Established in 1820 and opened to students in 1831, the University of Alabama is the oldest and largest of the publi ...

in 1984 and completed his postdoctoral training as a research fellow in pathology at Harvard Medical School. He was a faculty member at

Dana–Farber Cancer Institute Dana–Farber Cancer Institute is a comprehensive cancer treatment and research institution in Boston, Massachusetts. Dana–Farber is the founding member of Dana–Farber/Harvard Cancer Center, Harvard's Comprehensive Cancer Center designated b ...

and

Harvard Medical School Harvard Medical School (HMS) is the graduate medical school of Harvard University and is located in the Longwood Medical and Academic Area, Longwood Medical Area of Boston, Massachusetts. Founded in 1782, HMS is one of the oldest medical schools ...

from 1985 to 1998 before joining Duke University in 1993 as its founding chairman of immunology. Tedder studies the structure and function of B lymphocyte cell surface molecules that regulate B cell function, activation, and signal transduction. He currently has 401 total publications and 25 issued patents relating to B cells and their products, including CD19, CD20, CD22, CD83, and L-selectin. He has founded four biotherapeutic companies, including Angelica Therapeutics, Cellective Therapeutics, Cellective BioTherapy and most recently, Antigenomycs, Inc. The drug Tedder developed at Cellective Therapeutics,

inebilizumab Inebilizumab, sold under the brand name Uplizna, is a medication for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults. The most common adverse reactions include urinary tract infection, headache, joint pain (arthralgi ...

, has now been approved for NMSOD use in the United States under the clinical name

Uplizna Inebilizumab, sold under the brand name Uplizna, is a medication for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults. The most common adverse reactions include urinary tract infection, headache, joint pain (arthralgi ...

References

{{DEFAULTSORT:Tedder, Thomas Duke University faculty University of Alabama alumni American immunologists 1956 births Living people